ROSEN, A Dedicated Counsel for Investors, Announces January 9 Deadline for Illumina, Inc. Securities Class Action - ILMN

ROSEN, a globally recognized investor rights law firm, has issued a reminder to the investors who acquired Illumina, Inc. ILMN shares during the period from September 21, 2020, to November 9, 2023, about the impending deadline of January 9, 2024. This pertains to a securities class action initiated due to alleged misrepresentations and omissions by the company that may have affected the stock's value within the aforementioned time frame. Illumina, Inc., an established American company in the biotechnology sector, is headquartered in San Diego, California, and was founded on April 1, 1998. The firm is specialized in producing advanced integrated systems designed for genetic variation analysis and biological function assessment, catering to the genotyping, sequencing, gene expression, and proteomics markets.

The Class Period and Allegations

Investors who acquired ILMN shares between September 21, 2020, and November 9, 2023, are alerted to the class action lawsuit's lead plaintiff deadline of January 9, 2024. The lawsuit alleges that during the Class Period, Illumina, Inc. made materially false and/or misleading statements and did not disclose adverse facts about the company's business, operations, and prospects. As a result, the firm's shares traded at artificially inflated prices during the Class Period.

Legal Recourse for Illumina Shareholders

ROSEN Law Firm is mobilizing investors who have been negatively impacted by the alleged corporate discrepancies. Shareholders seeking to play a principal role in the class action against Illumina, Inc. are advised to contact the firm prior to the January 9, 2024 deadline. This class action is an effort to recover the damages incurred by investors due to the alleged misleading information propagated by the company's management, which is claimed to have violated securities laws.

About Illumina, Inc.

Illumina, Inc. ILMN, with more than two decades since its inception, stands as a leader in genomics—an area of biotechnology that is revolutionizing the understanding and treatment of diseases, paving the way for personalized medicine. Through its cutting-edge technologies and comprehensive suite of products, Illumina has drastically accelerated the pace at which genetic insights can be obtained, making significant strides in the field of genomics research.

Investment, Illumina, Deadline